Ernest Loumaye

No ORCID on file · 13 papers in corpus · active 1997-2022

Study types

  • article 10
  • other 1
  • rct 1
  • review 1

Condition tags

  • endometriosis 7
  • mesh:D004715 3
  • adenomyosis 2
  • dyspareunia 2
  • dysmenorrhea 2
  • mesh:D004412 1
  • mesh:D004414 1
  • mesh:D017699 1
rct
Lancet (London, England) ·doi:10.1016/S0140-6736(22)01475-1

BACKGROUND: Uterine fibroids are common non-cancerous neoplasm that cause heavy menstrual bleeding and other signs. Linzagolix is an oral gonadotropin-releasing hormone receptor antagonist taken once per day that dose-dependently suppresses…

other 2022
Reproductive biomedicine online ·doi:10.1016/j.rbmo.2021.09.019

RESEARCH QUESTION: Does a once-daily regimen of linzagolix, a new oral gonadotrophin-releasing hormone (GnRH) antagonist, given at a fully suppressive dose (200 mg) for 12 weeks, followed by a partially suppressive dose (100 mg) for a furth…

article 2021
Journal of clinical medicine ·doi:10.3390/jcm10245794

(1) Background: The aim of the present pilot study was to study the effect of a new oral gonadotropin-releasing hormone antagonist on adenomyosis. (2) Methods: Eight premenopausal women, aged between 37 and 45 years, presenting with heavy m…

article 2019
·doi:10.1016/j.fertnstert.2019.07.935
article 2019
·doi:10.1097/01.aog.0000558837.48634.b6

INTRODUCTION: Linzagolix is a new, non-peptide, GnRH receptor antagonist being developed to treat endometriosis-associated pain (EAP). The EDELWEISS trial is a Phase 2b, double-blind, randomized, placebo-controlled, multicenter, dose-rangin…

article 2017
·doi:10.1210/jc.2017-01875

Context: OBE2109 is a potent, oral gonadotropin-releasing hormone receptor antagonist being developed for the treatment of sex-hormone-dependent diseases in women. Objective: We assessed the pharmacodynamics and safety of OBE2109 alone and …

article 2011
Human Reproduction ·doi:10.1093/humrep/der079

BACKGROUND: Steroid sulfatase (STS) is involved in estrogen biosynthesis and expressed in eutopic and ectopic endometrium of disease-free and endometriosis patients. The present study was designed to investigate its role in endometriosis de…

article 2011
·doi:10.1097/ogx.0b013e31823d8bed

Endometriosis is an estrogen-dependent disorder. Treatment with hormonal therapy suppresses estrogen and leads to regression of lesions. However, hormonal therapy is associated with significant morbidity, adverse effects, and recurrence of …

article 2011
·doi:10.1093/humrep/26.s1.80
article 2009
Human Reproduction ·doi:10.1093/humrep/dep199

BACKGROUND: Aromatase has been reported to be involved in estrogen biosynthesis and expressed in eutopic and ectopic endometrium of endometriosis patients. The objective of the present study was to investigate its expression and localizatio…

article 2009
Gynecologic and obstetric investigation ·doi:10.1159/000240672

BACKGROUND/AIMS: Endometriosis is known to be an estrogen-dependent disease. However, only a few studies have analyzed the effect of estrogen treatment in mice xenotransplanted with human endometrium. The objective of this study was to adap…

review 2001
·doi:10.1016/s0015-0282(01)02878-3
article 1997
·doi:10.1016/s0015-0282(97)81402-1